The Curative and Palliative Potential of the Monoclonal Antibody MOv18 Labelled with ²¹¹At in Nude Mice with Intraperitoneally growing Ovarian Cancer Xenografts - A Long-Term Study

References

• Bolis G, Villa A, Guarnerio P, et al. Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy. Cancer 1996; 77: 128–31.
   PubMedGoogle Scholar
• Markman M. Intraperitoneal therapy of ovarian cancer. Semin Oncol 1998; 25: 356–60.
   PubMed Web of Science ®Google Scholar
• Thomas GM. Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer? Gyn Oncol 1993; 51: 97–103.
   PubMedGoogle Scholar
• Hird V, Maraveyas A, Snook D, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68: 403–6.
   PubMed Web of Science ®Google Scholar
• Crippa F, Bolis G, Seregni E, et al. Single-dose intraperi-toneal radioimmunotherapy with the murine monoclonal anti-body 1-131 MOvl 8: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 1995; 31A: 686–90.
   PubMed Web of Science ®Google Scholar
• Zalutsky MR, Bigner DD. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncol 1996; 35: 373–9.
   PubMed Web of Science ®Google Scholar
• Andersson H, Lindegren S, Back T, Jacobsson L, Leser G, Horvath G. Radioimmunotherapy of nude mice with in-traperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal anti-body M0v18. Anticancer Res 2000; 20: 459–62.
   PubMed Web of Science ®Google Scholar
• Markman M, Cleary S, Lucas WE, Howell SB. Intraperi-toneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other ma-lignancies principally involving the peritoneal cavity. J Clin Oncol 1985; 3: 925–31.
   PubMed Web of Science ®Google Scholar
• Buckman R, De Angelis C, Shaw P, et al. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol 1992; 47: 102–9.
   PubMed Web of Science ®Google Scholar
• Ward B, Mather S, Shepherd J, et al. The treatment of intraperitoneal malignant disease with monoclonal antibody guided "'I radiotherapy. Br J Cancer 1988; 58: 658–62.
   PubMed Web of Science ®Google Scholar
• Boerman OC, van Niekerk CC, Makkink K, Hanselaar TGJM, Kenemans P, Poels LG. Comparative immunohisto-chemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens. Int J Gyn Path 1991; 10: 15–25.
   PubMed Web of Science ®Google Scholar
• Miotti S, Canevari S, Me'nard S, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int J Cancer 1987; 39: 297–303.
   Google Scholar
• Campbell IG, Jones TA, Foulkes WD, Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res 1991; 51: 5329–38.
   PubMed Web of Science ®Google Scholar
• Lindegren S, Skarnemark G, Jacobsson L, Karlsson B. Chlo-ramine-T in high-specific-activity radioiodination of antibod-ies using N-succinimidy1-3-(trimethylstannyl)benzoate as an intermediate. Nucl Med Biol 1998; 25: 659–65.
   PubMedGoogle Scholar
• Andersson H, Lindegren S, Back T, Jacobsson L, Leser G, Horvath G. Biokinetics of the monoclonal antibodies MOv 18, OV 185 and OV 197 labelled with 1251 according to the m-MeATE method or the Iodogen method in nude mice with ovarian cancer xenografts. Acta Oncol 1999; 38: 323–8.
   PubMedGoogle Scholar
• Mantovani L, Me'nard S, Mezzanzanica D, Miotti S, Pupa SM, Colnaghi MI. Evaluation of the immunoreactive fraction of an anti-tumour monoclonal antibody. Br J Cancer 1990; 62 (Suppl X): 15–7.
   Google Scholar
• Miotti S, Alberti S, Facheris P, et al. Membrane association and shedding of the GPI-anchored Ca-M0v18 antigen in human ovary carcinoma cells. Int J Cancer 1992; 51: 499–505.
   PubMed Web of Science ®Google Scholar
• Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn Jr PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunological Methods 1984; 72: 77–89.
   Google Scholar
• Hamilton TC, Young RC, Louie KG, et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res 1984; 44: 5286–90.
   PubMed Web of Science ®Google Scholar
• Larsen RH, Hoff P, Vergote IB, et al. Alpha-particle radio-therapy with 'At-labeled monodisperse polymer particles, 'At-labeled IgG proteins, and free 211At in a murine in-traperitoneal tumor model. Gyn Oncol 1995; 57: 9–15.
   PubMedGoogle Scholar
• Bloomer WD, McLaughlin WH, Lambrecht RM, et al. 211At -radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y. Int J Radiat Oncol Biol Phys 1984; 10: 341–8.
   PubMedGoogle Scholar
• Horak E, Hartmann F, Garmestani K, et al. Radioim-munotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med 1997; 38: 1944–50.
   PubMedGoogle Scholar
• Bombardieri E, Ferrari L, Spinelli A, Maffioli L, Seregni E, Buraggi G. Radioimmunotherapy of ovarian cancer with radiolabelled monoclonal antibodies: biological basis, present status and future perspectives. Anticancer Res 1997; 17: 1719–30.
   PubMedGoogle Scholar
• Epenetos AA, Hooker G, Krausz T, Snook D, Bodmer WF, Taylor-Papadimitriou J. Antibody-guided irradiation of ma-lignant ascites in ovarian cancer: a new therapeutic method possessing specificity against cancer cells. Obstet Gyn 1986; 68 (Suppl 3): 71S–74.
   Google Scholar
• Lind SE, Cashavelly B, Fuller AF. Resolution of malignant ascites after intraperitoneal chemotherapy in women with carcinoma of the ovary. Surg Gyn Obstet 1988; 166: 519–22.
   Google Scholar
• Card RY, Cole DR, Henscke UK. Summary of ten years of the use of radioactive colloids in intracavtary therapy. J Nucl Med 1960; 1: 195–8.
   Google Scholar
• Rath U, Kaufmann M, Schmid H, et al. Effecy of intraperi-toneal recombinat human tumour necrosis factor alpha on malignant ascites. Eur J Cancer 1991; 27: 121–5.
   PubMed Web of Science ®Google Scholar
• Bezwoda WR, Seymour L, Dansey R. Intraperitoneal recom-binant interferon-alpha 2b for recurrrent malignant ascites due to ovarian cancer. Cancer 1989; 64: 1029–33.
   Google Scholar
• Reist CJ, Foulon CF, Alston K, Bigner DD, Zalutsky MR. Astatine-211 labeling of internalizing anti-EGFRvIII mono-clonal antibody using N-succinimidyl 54211At]astato-3-pyridinecarboxylate. Nucl Med Biol 1999; 26: 405–11.
   Google Scholar